NEW YORK (GenomeWeb) – Fitch Ratings today affirmed the long-term debt ratings of Agilent Technologies at BBB+ and said that the company's rating outlook is stable.

The rating actions apply to about $1.6 billion of debt as of Oct. 31. Agilent today also said that it completed the spin off of its electronic measurement business called Keysight Technologies, which has begun trading on the New York Stock Exchange under ticker symbol KEYS.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.